Ozempic is FDA-approved only for adults, meaning you need to be at least 18 years old to receive it as prescribed on its label. The drug is specifically indicated for adults with type 2 diabetes, and the FDA label states plainly that “safety and efficacy of Ozempic have not been established in pediatric patients.” That said, the age picture gets more nuanced when you consider other brand names of the same drug and the reality of off-label prescribing.
What the FDA Label Actually Says
Ozempic contains semaglutide, a weekly injection approved to improve blood sugar control in adults with type 2 diabetes. The label makes no provision for pediatric dosing and explicitly notes that it is not known whether Ozempic is safe or effective in children. The oral version of semaglutide, sold as Rybelsus, carries the same restriction: adults only, with no established safety or effectiveness in patients under 18.
Wegovy: The Same Drug With a Lower Age Limit
Here’s where it gets confusing. Semaglutide is also sold under the brand name Wegovy, which is approved for weight management rather than diabetes. Wegovy is FDA-approved for children aged 12 and older who meet the clinical definition of obesity based on age- and sex-specific BMI cutoffs. In adults, it’s approved for those with a BMI of at least 30, or at least 27 with a weight-related health condition.
So the same molecule has two different age thresholds depending on the brand and the condition being treated. If you’re a parent researching semaglutide for a teenager, Wegovy is the version with pediatric approval, not Ozempic. The doses differ between the two products, and they aren’t interchangeable.
Off-Label Use in Teens
Doctors can legally prescribe any approved medication off-label, meaning for a use, age group, or condition not specifically listed on the FDA label. CDC data confirms that semaglutide under the Ozempic brand is sometimes prescribed off-label to adolescents aged 12 to 17 with obesity or type 2 diabetes. This isn’t uncommon in medicine, but it does mean there’s less formal evidence backing that specific use compared to an FDA-approved indication.
Whether insurance covers off-label Ozempic for a minor is a separate question entirely. Most insurers base coverage on FDA-approved indications, so a prescription for Ozempic in a teenager may face prior authorization hurdles or outright denial, even if a doctor considers it medically appropriate.
Why Pediatric Data Is Still Limited
Clinical trials testing semaglutide in adolescents have been conducted, but the broader question of how the drug affects growing bodies over the long term remains open. A 2025 paper in the Journal of Adolescent Health called for “robust evidence related to healthy growth and development,” noting that most of what we know about semaglutide comes from adult populations. Adolescence involves rapid changes in bone density, hormonal balance, and body composition, and researchers have flagged that results in adults don’t automatically translate to teenagers still going through those changes.
This doesn’t mean semaglutide is dangerous for teens. It means the long-term picture is incomplete, which is one reason the FDA approved the weight management version (Wegovy) for ages 12 and up while keeping the diabetes version (Ozempic) limited to adults. Wegovy went through dedicated pediatric trials; Ozempic did not.
No Upper Age Limit, but Extra Caution Over 60
There is no maximum age for Ozempic. Clinical trials for semaglutide products included thousands of patients over 65, and hundreds over 75. The drug doesn’t require dose adjustments based on age alone.
That said, older adults face a distinct set of risks. Semaglutide causes weight loss even when prescribed for diabetes, and in people over 60, that weight loss can disproportionately come from muscle and bone rather than fat. Loss of muscle mass in older adults raises the risk of falls, fractures, and loss of independence. Nutrient deficiencies are another concern, since the drug suppresses appetite significantly. Dr. John Batsis, a geriatrics specialist at UNC, has noted that “the older you are, the more reason you have to be cautious” because aging bodies respond differently than younger ones. For older patients, strength training and adequate protein intake become especially important while on the medication.
The Quick Reference
- Ozempic (injection, for type 2 diabetes): Adults 18 and older only
- Rybelsus (oral tablet, for type 2 diabetes): Adults 18 and older only
- Wegovy (injection, for weight management): Ages 12 and older for obesity; adults for related conditions including liver disease and heart risk reduction
If you’re under 18 and your doctor is considering semaglutide, the conversation will almost certainly center on Wegovy rather than Ozempic. If you’re an adult of any age, Ozempic is an option, though the risk-benefit balance shifts as you get older and preserving muscle and bone becomes a bigger priority.